Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

MAP3K8/Tpl2/COT Antibody (OTI3D9) - Azide and BSA Free, Novus Biologicals™
SDP

Mouse Monoclonal Antibody

Supplier:  Novus Biologicals NBP272589

Catalog No. NBP272589


Only null left
Add to Cart

Description

Description

MAP3K8/Tpl2/COT Monoclonal specifically detects MAP3K8/Tpl2/COT in Human, Mouse, Rat samples. It is validated for Western Blot.
Specifications

Specifications

MAP3K8/Tpl2/COT
Monoclonal
LYOPH
Western Blot 1:500
Cancer Osaka thyroid oncogene, c-COT, cot (cancer Osaka thyroid) oncogene, COTMEKK8, EC 2.7.11.25, ESTF, ESTFLJ10486, Ewing sarcoma transformant, mitogen-activated protein kinase kinase kinase 8, Proto-oncogene c-Cot, proto-oncogene serine/threoine protein kinase, Serine/threonine-protein kinase cot, Tpl-2, TPL2, Tumor progression locus 2, tumor progression locus-2
Mouse
52.7 kDa
100 μg
Primary
Reconstitute with PBS (pH 7.3). To use this carrier-free antibody for conjugation experiments, another round of desalting is highly recommended.
Store at -20°C. Avoid freeze-thaw cycles.
IgG1
Western Blot
OTI3D9
Unconjugated
Lyophilized from PBS (pH 7.3) with 8% Trehalose with No Preservative
MAP3K8
Human recombinant protein fragment corresponding to amino acids 277-461 of human MAP3K8(NP_005195) produced in E.coli.
Affinity Purified
Angiogenesis, Cancer, Protein Kinase
1326
Human, Mouse, Rat
Lyophilized
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.